Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 8.99B 7.86B 7.25B 6.68B 12.59B 866B 12.87B 86.64B 34.08B 424B 33.76B 33.02B 1,459B P/E 2026 *
-15x
P/E 2027 * -29.6x
Enterprise Value 8.74B 7.63B 7.04B 6.49B 12.24B 841B 12.51B 84.2B 33.12B 412B 32.81B 32.09B 1,418B EV / Sales 2026 *
9.82x
EV / Sales 2027 * 6.41x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ionis Pharmaceuticals, Inc.

1 day-0.48%
1 week-6.63%
Current month-31.40%
1 month-26.81%
3 months-28.16%
6 months-28.74%
Current year-31.25%
1 week 53.38
Extreme 53.38
57.91
1 month 53.38
Extreme 53.38
86.74
Current year 53.38
Extreme 53.38
86.74
1 year 40.03
Extreme 40.03
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Free

Chairman

7,670 0.0046%
7/1/26 Fiscal year

Director

42,224 0.0255%
7/1/26 Free

Director

7,670 0.0046%
Change 5-day change 1-year change 3-year change Capi.($)
-0.48%-6.63%+28.98%+28.89% 8.99B
+3.90%-0.39%+376.72%+599.59% 39.58B
-1.70%+4.46%+7.46%+57.67% 34.69B
-2.01%-0.76%+26.35%-6.83% 34.42B
+0.06%+0.34%+2.32%+29.30% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+68.48%+117.39% 15.36B
+1.12%+1.91%+15.90%+19.65% 14.05B
0.00%+1.36%+15.74%-30.62% 13.02B
-0.08%-3.01%+1,271.69%+649.69% 11.76B
Average +0.12%-0.63%+201.52%+162.74% 21.52B
Weighted average by Cap. +0.21%+0.06%+165.00%+180.26%

Financials

2026 *2027 *
Net sales 889M 777M 717M 661M 1.25B 85.63B 1.27B 8.57B 3.37B 41.94B 3.34B 3.27B 144B 1.39B 1.21B 1.12B 1.03B 1.95B 134B 1.99B 13.38B 5.26B 65.49B 5.21B 5.1B 225B
Net income -598M -523M -482M -445M -838M -57.61B -857M -5.77B -2.27B -28.22B -2.25B -2.2B -97.13B -309M -270M -249M -230M -433M -29.79B -443M -2.98B -1.17B -14.59B -1.16B -1.14B -50.22B
Net Debt -252M -221M -204M -188M -354M -24.32B -362M -2.43B -957M -11.91B -948M -927M -40.99B -86.16M -75.29M -69.48M -64.04M -121M -8.3B -123M -830M -327M -4.06B -324M -316M -13.99B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
26-07-17 US$54.39 -0.48% 2,572,809
26-07-16 US$54.65 -0.15% 3,805,259
26-07-15 US$54.73 -0.36% 3,577,545
26-07-14 US$54.93 -3.21% 4,700,265
26-07-13 US$56.75 -2.58% 5,097,949
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
54.39USD
Average target price
92.95USD
Spread / Average Target
+70.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock